Literature DB >> 33322203

Parameters for Irreversible Inactivation of Monoamine Oxidase.

Rona R Ramsay1, Livia Basile2, Antonin Maniquet1, Stefanie Hagenow1, Matteo Pappalardo2, Maria Chiara Saija2, Sharon D Bryant3, Alen Albreht4, Salvatore Guccione2.   

Abstract

The irreversible inhibitors of monoamine oxidases (MAO) slow neurotransmitter metabolism in depression and neurodegenerative diseases. After oxidation by MAO, hydrazines, cyclopropylamines and propargylamines form a covalent adduct with the flavin cofactor. To assist the design of new compounds to combat neurodegeneration, we have updated the kinetic parameters defining the interaction of these established drugs with human MAO-A and MAO-B and analyzed the required features. The Ki values for binding to MAO-A and molecular models show that selectivity is determined by the initial reversible binding. Common to all the irreversible inhibitor classes, the non-covalent 3D-chemical interactions depend on a H-bond donor and hydrophobic-aromatic features within 5.7 angstroms apart and an ionizable amine. Increasing hydrophobic interactions with the aromatic cage through aryl halogenation is important for stabilizing ligands in the binding site for transformation. Good and poor inactivators were investigated using visible spectroscopy and molecular dynamics. The initial binding, close and correctly oriented to the FAD, is important for the oxidation, specifically at the carbon adjacent to the propargyl group. The molecular dynamics study also provides evidence that retention of the allenyl imine product oriented towards FADH- influences the formation of the covalent adduct essential for effective inactivation of MAO.

Entities:  

Keywords:  FAD; adduct; computational modeling; enzyme kinetics; irreversible inhibition; pharmacophore; spectrum

Mesh:

Substances:

Year:  2020        PMID: 33322203      PMCID: PMC7763263          DOI: 10.3390/molecules25245908

Source DB:  PubMed          Journal:  Molecules        ISSN: 1420-3049            Impact factor:   4.411


  58 in total

1.  Binding of rasagiline-related inhibitors to human monoamine oxidases: a kinetic and crystallographic analysis.

Authors:  Claudia Binda; Frantisek Hubálek; Min Li; Yaacov Herzig; Jeffrey Sterling; Dale E Edmondson; Andrea Mattevi
Journal:  J Med Chem       Date:  2005-12-29       Impact factor: 7.446

Review 2.  Lights and shadows on monoamine oxidase inhibition in neuroprotective pharmacological therapies.

Authors:  Claudia Binda; Erika M Milczek; Daniele Bonivento; Jin Wang; Andrea Mattevi; Dale E Edmondson
Journal:  Curr Top Med Chem       Date:  2011-11       Impact factor: 3.295

Review 3.  Propargylamine as functional moiety in the design of multifunctional drugs for neurodegenerative disorders: MAO inhibition and beyond.

Authors:  Frank T Zindo; Jacques Joubert; Sarel F Malan
Journal:  Future Med Chem       Date:  2015       Impact factor: 3.808

4.  Mutation of surface cysteine 374 to alanine in monoamine oxidase A alters substrate turnover and inactivation by cyclopropylamines.

Authors:  Ana Paula B Vintém; Nigel T Price; Richard B Silverman; Rona R Ramsay
Journal:  Bioorg Med Chem       Date:  2005-05-16       Impact factor: 3.641

5.  Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease.

Authors:  Irene Bolea; Jordi Juárez-Jiménez; Cristóbal de Los Ríos; Mourad Chioua; Ramón Pouplana; F Javier Luque; Mercedes Unzeta; José Marco-Contelles; Abdelouahid Samadi
Journal:  J Med Chem       Date:  2011-11-15       Impact factor: 7.446

6.  Monoamine oxidase A inhibitory potency and flavin perturbation are influenced by different aspects of pirlindole inhibitor structure.

Authors:  Robert M G Hynson; Johan Wouters; Rona R Ramsay
Journal:  Biochem Pharmacol       Date:  2003-06-01       Impact factor: 5.858

7.  Crystal structures of monoamine oxidase B in complex with four inhibitors of the N-propargylaminoindan class.

Authors:  Claudia Binda; Frantisek Hubálek; Min Li; Yaacov Herzig; Jeffrey Sterling; Dale E Edmondson; Andrea Mattevi
Journal:  J Med Chem       Date:  2004-03-25       Impact factor: 7.446

8.  Structure-activity relationships in the oxidation of benzylamine analogues by bovine liver mitochondrial monoamine oxidase B.

Authors:  M C Walker; D E Edmondson
Journal:  Biochemistry       Date:  1994-06-14       Impact factor: 3.162

Review 9.  Assessment of Enzyme Inhibition: A Review with Examples from the Development of Monoamine Oxidase and Cholinesterase Inhibitory Drugs.

Authors:  Rona R Ramsay; Keith F Tipton
Journal:  Molecules       Date:  2017-07-15       Impact factor: 4.411

10.  The novel cholinesterase-monoamine oxidase inhibitor and antioxidant, ladostigil, confers neuroprotection in neuroblastoma cells and aged rats.

Authors:  Orit Bar-Am; Orly Weinreb; Tamar Amit; Moussa B H Youdim
Journal:  J Mol Neurosci       Date:  2008-08-27       Impact factor: 2.866

View more
  3 in total

1.  Soyasapogenol-B as a Potential Multitarget Therapeutic Agent for Neurodegenerative Disorders: Molecular Docking and Dynamics Study.

Authors:  Danish Iqbal; Syed Mohd Danish Rizvi; Md Tabish Rehman; M Salman Khan; Abdulaziz Bin Dukhyil; Mohamed F AlAjmi; Bader Mohammed Alshehri; Saeed Banawas; Qamar Zia; Mohammed Alsaweed; Yahya Madkhali; Suliman A Alsagaby; Wael Alturaiki
Journal:  Entropy (Basel)       Date:  2022-04-23       Impact factor: 2.738

2.  Design, synthesis, and evaluation of 3,7-substituted coumarin derivatives as multifunctional Alzheimer's disease agents.

Authors:  Sheunopa C Mzezewa; Sylvester I Omoruyi; Luke S Zondagh; Sarel F Malan; Okobi E Ekpo; Jacques Joubert
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

3.  Effects of Natural Monoamine Oxidase Inhibitors on Anxiety-Like Behavior in Zebrafish.

Authors:  Oihane Jaka; Iñaki Iturria; Marco van der Toorn; Jorge Hurtado de Mendoza; Diogo A R S Latino; Ainhoa Alzualde; Manuel C Peitsch; Julia Hoeng; Kyoko Koshibu
Journal:  Front Pharmacol       Date:  2021-05-13       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.